Original contributionHuman DNA topoisomerase II-alpha: A new marker of cell proliferation in invasive breast cancer☆
References (52)
- et al.
Differential patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development
Biochim Biophys Acta
(1992) - et al.
The distribution of DNA topoisomerase II isoforms in differentiated adult mouse tissues
Biochim Biophys Acta
(1993) - et al.
Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung
Biochim Biophys Acta
(1995) - et al.
Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase IIβ
J Biol Chem
(1995) - et al.
Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins
J Biol Chem
(1988) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding
Anal Biochem
(1976)- et al.
A homogeneous type II DNA topoisomerase from Hela cell nuclei
J Biol Chem
(1981) - et al.
Breast cancer
N Engl J Med
(1992) - et al.
A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors
N Engl J Med
(1989) - et al.
A randomized clinical trial evaluating tamoxifen in the treatment of patients with nodenegative breast cancer who have estrogen-receptor-positive tumors
N Engl J Med
(1989)
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer
N Engl J Med
(1989)
Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer
N Engl J Med
(1989)
Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer
Science
(1989)
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
N Engl J Med
(1994)
Her2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
J Clin Oncol
(1992)
Prediction of early course of breast carcinoma by thymidine labeling
Cancer
(1983)
Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry
N Engl J Med
(1989)
Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients
J Clin Oncol
(1992)
Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: Relationship with DNA binding affinity and cytotoxicity
Biochemistry
(1990)
Characterization and immunological identification of cDNA clones encoding two human topoisomerase isozymes
Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II
Biochemistry
(1989)
Altered topoisomerase II-alpha in a drug-resistant small cell lung cancer cell line selected in VP-16
Cancer Res
(1993)
A novel mutant topoisomerase II-alpha present in a VP-16-resistant human melanoma cell lines has a deletion of alanine 429
Biochemistry
(1994)
Cytoplasmic localization of a mutant Mr 160,000 topoisomerase II-alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line
Cancer Res
(1995)
Functional expression of human topoisomerase II-alpha in yeast: Mutations at amino acids 450 or 803 of topoisomerase II-alpha result in enzymes that can confer resistance to anti-topoisomerase II agents
Cancer Res
(1996)
Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes
Br J Cancer
(1993)
Cited by (131)
Topoisomerase IIα immunoexpression in feline mammary carcinomas: A correlation with Ki67 immunoexpression and the mitotic count
2023, Research in Veterinary ScienceRole of Endothelium in Doxorubicin-Induced Cardiomyopathy
2018, JACC: Basic to Translational ScienceCitation Excerpt :The beta isoenzyme of topoisomerase II is elevated in terminally differentiated cells, such as endothelial cells of the coronary microvessels (62,63). On the other hand, topoisomerase IIα is increased in dividing cells, such as cancer cells (64). Doxorubicin binds and stabilizes the cleavable complex of both topoisomerase IIα and β, which leads to unrepaired double-strand DNA breaks in both cancer and endothelial cells (65).
- ☆
Supported by a research educational grant from Pharmacia and Upjohn, San Clemente, CA.
Copyright © 1997 Published by Elsevier Inc.